FLEURY S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.59 BRL | +4.14% |
|
+4.14% | -19.12% |
| Mar. 08 | Transcript : Fleury S.A., Q4 2023 Earnings Call, Mar 08, 2024 | |
| Mar. 07 | Fleury S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | 7.79B 1.52B | Sales 2025 * | 8.36B 1.63B | Capitalization | 7.96B 1.56B |
|---|---|---|---|---|---|
| Net income 2024 * | 637M 124M | Net income 2025 * | 795M 155M | EV / Sales 2024 * | 1.46 x |
| Net Debt 2024 * | 3.44B 672M | Net Debt 2025 * | 2.67B 521M | EV / Sales 2025 * | 1.27 x |
| P/E ratio 2024 * |
12.7
x | P/E ratio 2025 * |
10.2
x | Employees | 27,300 |
| Yield 2024 * |
2.34% | Yield 2025 * |
5.16% | Free-Float | 43.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fleury S.A.
More press releases
| 1 day | +4.14% | ||
| 1 week | +4.14% | ||
| Current month | -2.73% | ||
| 1 month | -1.95% | ||
| 3 months | -11.09% | ||
| 6 months | -1.55% | ||
| Current year | -19.12% |
1 week
14.35
14.89
1 month
13.6915.03
Current year
13.6918.08
1 year
13.5518.96
3 years
12.8926.55
5 years
12.8932.47
10 years
6.1032.47
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 00-12-31 | |
| Director of Finance/CFO | 63 | 21-07-22 | |
| Chief Tech/Sci/R&D Officer | 48 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | - | |
| Director/Board Member | 78 | 13-04-08 | |
João Teixeira
BRD | Director/Board Member | 57 | 21-04-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.43% | 2 M€ | -14.14% | ||
| 0.24% | 15 M€ | -3.58% | ||
| 0.02% | 4 M€ | -4.41% | - | |
| 0.01% | 117 M€ | +1.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 14.59 | +4.14% | 901 300 |
| 24-04-26 | 14.61 | -0.34% | 2,941,300 |
| 24-04-25 | 14.66 | +0.89% | 1,734,000 |
| 24-04-24 | 14.53 | -1.29% | 3,007,400 |
| 24-04-23 | 14.72 | +5.07% | 11,137,400 |
Delayed Quote Sao Paulo, April 29, 2024 at 12:11 pm EDT
More quotes
Fleury S.A. specializes in clinical diagnosis, treatment and analysis services.
At the end of 2018, the group operated a network of 187 patient care centers and 23 hospital centers under Fleury, Weinmann, Clínica Felipe Mattoso, a +, Labs a + and Diagnoson a + brands.
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
14.61
BRL
Average target price
19.9
BRL
Spread / Average Target
+36.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.12% | 1.55B | |
| -16.58% | 8.25B | |
| +41.50% | 3.58B | |
| -35.59% | 2.46B | |
| -7.88% | 2.46B | |
| -8.95% | 2.38B | |
| -3.99% | 1.81B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -15.03% | 1.03B |
- Stock Market
- Equities
- FLRY3 Stock
